Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs TG Therapeutics Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.67, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CIBR | TGTX | |
|---|---|---|
52-Week High | $100.60 | $59.06 |
52-Week Low | $60.74 | $26.94 |
Market Cap | — | $7.64B |
Sector | — | Health |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.39, down 0.21% on the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF benefits from strong cybersecurity spending trends, with global expenditures exceeding $300 billion in 2026 (Gartner, 2026-06-04), and has outperformed the S&P 500 year-to-date. Recent institutional activity shows mixed signals, with Bank of America reducing its stake while First Trust Advisors increased its position.
Outlook remains positive due to secular growth in cybersecurity demand, though high RSI levels suggest near-term consolidation risks. Investment opportunity lies in AI-driven security needs, but concentration in tech and valuation sensitivity are key risks for investors.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
